Phase 4 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Breast Cancer Group (Cohort A):
- People who have breast cancer that has spread to other parts of the body, and whose cancer is driven by hormones (hormone receptor positive)
- People whose doctor plans to treat them with hormone therapy and a specific type of targeted therapy called a CDK4/6 inhibitor — either Ribociclib or Palbociclib — as their first treatment for the cancer that has spread
- People aged 18 or older
- People who are able to give consent by speaking (rather than in writing)
- People who are willing and able to fill in questionnaires as required by the study
Prostate Cancer Group (Cohort B):
- People who have prostate cancer that has spread to other parts of the body and is still responding to hormone-lowering treatment
- People whose doctor plans to treat them with a hormone-blocking medication (either enzalutamide, apalutamide, or abiraterone acetate) alongside treatment to reduce testosterone levels
- People aged 18 or older
- People who are able to give consent by speaking (rather than in writing)
- People who are willing and able to fill in questionnaires as required by the study
Who may not be able to join:
Breast Cancer Group (Cohort A):
- People for whom there is a medical reason that prevents their hormone therapy or CDK4/6 inhibitor being taken in the morning or evening
- People whose doctor plans to use a CDK4/6 inhibitor called abemaciclib, as this medication needs to be taken twice a day
Prostate Cancer Group (Cohort B):
- People for whom there is a medical reason that prevents their hormone-blocking medication being taken in the morning or evening
- People whose doctor plans to use a medication called darolutamide, as this requires twice-daily dosing
- People whose treatment plan includes a chemotherapy called docetaxel alongside their hormone-blocking medication
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Marie-France Savard, MD, The Ottawa Hospital
Phone: 613-737-7700
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Feasibility: accrual per site; Feasibility: participation rate; Feasibility: number of participants who received allocated intervention
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.